Daré Bioscience Reports First Quarter 2026 Financial Results and Provides Business Update

About this update from Dare Bioscience, Inc.

Company Highlights Second Positive DSMB Review of Interim Data from Ovaprene® Phase 3 Clinical Trial, DARE to PLAY™ Anticipated Dispensing Commencement and Flora Sync LF5™ Commercial Launch Summer 2026; First Product Revenue Expected in June 2026; Call Hosted During National Women’s Health Week. Conference Call and Webcast Today at 4:30 p.m. ET “We are hosting our financial results and business update call from New York, in the middle of National Women’s Health Week,” said Sabrina Martucci Johnson, President and Chief Executive Officer of Daré Bioscience. “Daré was built on the conviction that women’s health is an investment-grade category – not a niche, not a nice-to-have, not a pink ribbon in a press release. A category worth building, funding, and holding accountable for delivering to women the healthcare options they deserve. This week alone, we announced a second consecutive positive DSMB review of interim data from our ongoing Phase 3 clinical trial of Ovaprene – two consecutive positive reviews of interim data for a product candidate that could be the first FDA-approved, hormone-free, monthly contraceptive. And with the planned commencement of DARE to PLAY dispensing and the anticipated commercial launch of Flora Sync LF5, summer 2026 is expected to mark the first time Daré Bioscience records direct product revenue. We built this company to change how women experience healthcare. We believe that change is beginning in earnest now.” SAN DIEGO, May 14, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women’s health between promising science and real-world solutions, today reported financial results for the quarter ended March 31, 2026, and provided a business update. “Daré is a product company. Its mission is to develop and bring to market clinically-studied and differentiated women’s health products – products with clinical data behind them, addressing gaps where in our view little to no adequate options exist today. The DARE Health Hub and its telehealth infrastructure are built to put those products in women’s hands efficiently and discreetly. Telehealth is an access tool; the products are the point. We believe product revenue from these commercially launched products, alongside capital raised through equity financing and non-dilutive grant funding, will giv...

View stock analysis, news, and events for Dare Bioscience, Inc.